Expression of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 in Quiescent Endothelia [PDF]
Journal of Histochemistry & Cytochemistry, 2002 The vascular endothelial growth factor (VEGF) family is involved in angiogenesis, and therefore VEGFs are considered as targets for anti-angiogenic therapeutic strategies against cancer. However, the physiological functions of VEGFs in quiescent tissues are unclear and may interfere with such systemic therapies.
Witmer, Antonella N. +4 more
openaire +3 more sources
Chinese Journal of Physiology, 2019 Preeclampsia (PE) is the leading cause of maternal and fetal morbidity and mortality. It complicates around 2%–10% pregnancies worldwide due to imbalance between proangiogenic and anti-angiogenic factors, leading to incomplete placentation, ischemia, and
Zaima Ali +4 more
doaj +1 more source
Hypoxia-induced reactive oxygen species cause chromosomal abnormalities in endothelial cells in the tumor microenvironment. [PDF]
PLoS ONE, 2013 There is much evidence that hypoxia in the tumor microenvironment enhances tumor progression. In an earlier study, we reported abnormal phenotypes of tumor-associated endothelial cells such as those resistant to chemotherapy and chromosomal instability ...
Miyako Kondoh +8 more
doaj +1 more source
Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. [PDF]
PLoS ONE, 2011 We identified that the angiotensin receptor antagonist, candesartan, has profound neurovascular protective properties when administered after ischemic stroke and was associated with a proangiogenic state at least partly explained by vascular endothelial ...
Weihua Guan +9 more
doaj +1 more source
Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy [PDF]
, 2007 Maternal endothelial dysfunction in preeclampsia is associated with increased soluble fms-like tyrosine kinase-1 (sFlt-1), a circulating antagonist of vascular endothelial growth factor and placental growth factor.
Kellems, Rodney E. +19 more
core +1 more source
Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor 1 [PDF]
Journal of Biological Chemistry, 2008 Vascular endothelial growth factor receptor-1 (VEGFR-1, also known as Flt-1) is involved in complex biological processes often associated to severe pathological conditions like cancer, inflammation, and metastasis formation. Consequently, the search for antagonists of Flt-1 has recently gained a growing interest.
Ponticelli S +10 more
openaire +5 more sources
Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. [PDF]
, 2008 Antihypertensive drugs are believed to lower blood pressure in pre-eclampsia by direct or central vasodilatory mechanisms. However, they could also act by decreasing production of anti-angiogenic proteins involved in the pathophysiology of hypertension ...
Muttukrishna Shanthi +11 more
core +2 more sources
The functions and applications of A7R in anti-angiogenic therapy, imaging and drug delivery systems
Asian Journal of Pharmaceutical Sciences, 2019 Vascular endothelial growth factor receptor 2 (VEGFR-2) and neuropilin-1 (NRP-1) are two prominent antiangiogenic targets. They are highly expressed on vascular endothelial cells and some tumor cells.
Lu Lu +4 more
doaj +1 more source
Patologìâ, 2019 Aim – to study VEGF-A, VEGFR-1, VEGFR-2 and CD34 immunohistochemical expression on the I, II, III, IV stages (pTNM) of colorectal adenocarcinoma development. Materials and methods.
M. A. Shyshkin
doaj +1 more source
Platelets, 2022 CIGB-247 is a vascular endothelial growth factor (VEGF)-based active immunotherapy and it is currently under investigation for cancer treatment. This specific active immunotherapy encompasses two vaccine candidates that use a human VEGF variant molecule ...
Javier Sánchez Ramírez +3 more
doaj +1 more source